NO20076120L - Stabile nanopartikkelformuleringer - Google Patents

Stabile nanopartikkelformuleringer

Info

Publication number
NO20076120L
NO20076120L NO20076120A NO20076120A NO20076120L NO 20076120 L NO20076120 L NO 20076120L NO 20076120 A NO20076120 A NO 20076120A NO 20076120 A NO20076120 A NO 20076120A NO 20076120 L NO20076120 L NO 20076120L
Authority
NO
Norway
Prior art keywords
nanoparticle formulations
stable nanoparticle
formulations
stable
preparing
Prior art date
Application number
NO20076120A
Other languages
English (en)
Norwegian (no)
Inventor
Khawla Abdullah Abu-Izza
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of NO20076120L publication Critical patent/NO20076120L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20076120A 2005-05-05 2007-11-27 Stabile nanopartikkelformuleringer NO20076120L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67808605P 2005-05-05 2005-05-05
PCT/US2006/017059 WO2007086911A2 (en) 2005-05-05 2006-05-03 Stable nanoparticle formulations

Publications (1)

Publication Number Publication Date
NO20076120L true NO20076120L (no) 2007-11-27

Family

ID=38309654

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076120A NO20076120L (no) 2005-05-05 2007-11-27 Stabile nanopartikkelformuleringer

Country Status (16)

Country Link
US (1) US20080038359A1 (pt)
EP (1) EP1895982A2 (pt)
JP (1) JP5483874B2 (pt)
KR (2) KR20080015077A (pt)
CN (1) CN101252914B (pt)
AU (2) AU2006336414B2 (pt)
BR (1) BRPI0611433A2 (pt)
CA (1) CA2606861C (pt)
HK (1) HK1120417A1 (pt)
IL (1) IL187128A0 (pt)
MA (1) MA29492B1 (pt)
NO (1) NO20076120L (pt)
NZ (1) NZ562559A (pt)
RU (1) RU2409352C2 (pt)
WO (1) WO2007086911A2 (pt)
ZA (1) ZA200708633B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US7923478B2 (en) * 2006-12-28 2011-04-12 Bridgestone Corporation Nanoporous polymeric material and preparation method
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
WO2013041944A1 (en) 2011-09-19 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of micronized candesartan cilexetil
CN104174468B (zh) * 2014-08-27 2016-06-15 上海延安药业有限公司 粘稠性药物锆珠研磨方法
IL307931A (en) * 2016-04-15 2023-12-01 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as EHMT1 and EHMT2 inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263310A (en) * 1974-03-02 1981-04-21 Boehringer Ingelheim Gmbh 8-Bromo-6-(o-chloro-phenyl)-4H-S-triazolo-[3,4,-c]-thieno-[2,3-e]-1,4-diazepines and salts thereof
US4322440A (en) * 1980-06-25 1982-03-30 New York University Anticonvulsive compositions and method of treating convulsive disorders
CA2019719A1 (en) * 1990-06-25 1991-12-25 William J. Thompson Mouthwash
DE4131562A1 (de) * 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)
JPH05305226A (ja) * 1992-04-28 1993-11-19 Takeda Chem Ind Ltd 粒子及びその製造法
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
FR2754262B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
US6337092B1 (en) * 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
IL140276A0 (en) * 1998-06-19 2002-02-10 Rtp Pharma Inc Processes to generate submicron particles of water-insoluble compounds
US6200590B1 (en) * 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
DE60020732T2 (de) * 1999-12-20 2006-05-11 Kerkhof, Nicholas J., Rio Vista Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung
FR2813306B1 (fr) * 2000-08-23 2005-10-21 Sanofi Synthelabo Aminoalkybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant
US7105176B2 (en) * 2000-11-29 2006-09-12 Basf Aktiengesellschaft Production of solid preparations of water-soluble, sparingly water-soluble or water-insoluble active compounds
ES2403238T3 (es) * 2000-12-07 2013-05-16 Takeda Gmbh Preparación farmacéutica en forma de una suspensión que comprende un ingrediente activo lábil en medio ácido
MXPA03006958A (es) * 2001-02-05 2003-11-18 Upjohn Co Composicion para administracion rectal de farmaco antibacterial de oxazolidinona.
GB0127832D0 (en) * 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
MXPA04005497A (es) * 2001-12-06 2004-10-11 Ranbaxy Lab Ltd Composiciones nanoparticuladas de isotretinoin.
CN1275589C (zh) * 2002-05-31 2006-09-20 王玉万 含抗寄生虫药物的缓释注射剂
US8003690B2 (en) * 2002-12-13 2011-08-23 Jagotec Ag Topical nanoparticulate spironolactone formulation
AU2003239845A1 (en) * 2003-05-07 2004-11-26 Ifac Gmbh And Co.Kg Compositions for the targetted release of fragrances and aromas
KR100603974B1 (ko) * 2003-12-05 2006-07-25 김갑식 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법

Also Published As

Publication number Publication date
EP1895982A2 (en) 2008-03-12
CA2606861A1 (en) 2007-08-02
CN101252914B (zh) 2013-03-27
AU2006336414B2 (en) 2011-11-24
ZA200708633B (en) 2009-01-28
WO2007086911A3 (en) 2008-04-17
RU2409352C2 (ru) 2011-01-20
WO2007086911A2 (en) 2007-08-02
HK1120417A1 (en) 2009-04-03
KR20080015077A (ko) 2008-02-18
AU2006336414A1 (en) 2007-08-02
JP2008540439A (ja) 2008-11-20
AU2010241245A1 (en) 2010-11-25
US20080038359A1 (en) 2008-02-14
IL187128A0 (en) 2008-06-05
RU2007145055A (ru) 2009-06-10
CN101252914A (zh) 2008-08-27
NZ562559A (en) 2011-03-31
CA2606861C (en) 2012-08-07
JP5483874B2 (ja) 2014-05-07
MA29492B1 (fr) 2008-05-02
BRPI0611433A2 (pt) 2010-09-08
KR20140002810A (ko) 2014-01-08

Similar Documents

Publication Publication Date Title
TW200716646A (en) (S)-N-methylnaltrexone
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
WO2009012303A3 (en) Therapeutic stable nanoparticles
NO20070785L (no) Sammensetninger for levering av svaert vannloselige medikamenter.
NO20090305L (no) Cyklosporin formuleringer
NO20085338L (no) Substituerte 1,3-difenylpropanderivater, sammensetninger og anvendelser derav
IL183274A0 (en) Method for producing sterile suspensions or lyophilisates of poorly soluble basic peptide complexes, pharmaceutical formulations containing the same, and use thereof as medicaments
NO20075136L (no) Nye liposompreparater
SI1909843T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
NO20091299L (no) Substituerte sulfonamidderivater
MY149601A (en) Masking the taste of powders
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
DK1543063T3 (da) Medikament levering
NO20076120L (no) Stabile nanopartikkelformuleringer
UA97629C2 (ru) Фармацевтическая композиция, имеющая противоопухолевую активность, и способы
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf
TW200640932A (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
DK1791872T3 (da) Biotinylerede hexadecasaccharider, farmaceutiske præparater og anvendelse heraf
MXPA05008902A (es) Soluciones de drogas en mentol.
ATE481392T1 (de) Benzimidazolderivate zur behandlung entzündlicher erkrankungen
NO20075508L (no) Stannsoporfinpreparater og administrering
DE602004022515D1 (de) Fenofibrate tablett und verfahren zur herstellung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application